Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

NCT07150247 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07150247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07150247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2025
Completion date
June 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 colorectal cancer